Saturday 17 October 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million. In the quarter to June 2026, revenue fell 37.7%, EPS fell 242.3% and free cash flow grew 23.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.12
0.19
−3.01%
Follow ALMS
Alumis Inc. (ALMS) P/E ratio
Alumis Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.1× (April 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.1× | 30.32% |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.1×
Ten-year median
0.0×
Current reading's percentile
67
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| VSTM Verastem, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ALMS Alumis Inc. | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)